Skip to main content
. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9

Table 3.

Health economic outcomes by infection type and pathogen (unadjusted)a–c

Abscess Cellulitis Wound
By infection typed Daptomycin Vancomycin Daptomycin Vancomycin Daptomycin Vancomycin
(n = 40) (n = 42) (n = 54) (n = 44) (n = 17) (n = 16)
 IRLOS, hours, mean (SD) 83.8 (53.8) 102.1 (75.4) 97.3 (61.5) 80.2 (43.5) 94.4 (63.4) 109.0 (59.0)
 Total LOS, hours, mean (SD) 94.8 (102.2) 105.6 (75.2) 101.7 (64.4) 85.1 (56.6) 103.0 (58.9) 139.3 (94.3)
 Total inpatient cost, 2012 US$, mean (SD)a 9515 (8501) 9432 (5955) 9871 (5805) 7415 (4750) 9814 (5927) 13,101 (7025)
Staphylococcus aureus e MRSA MSSA
By pathogen Daptomycin Vancomycin Daptomycin Vancomycin Daptomycin Vancomycin
(n = 58) (n = 43) (n = 39) (n = 27) (n = 14) (n = 10)
 IRLOS, hours, mean (SD) 98.4 (64.5) 101.2 (69.4) 98.5 (67.0) 85.9 (51.8) 84.5 (43.6) 136.2 (95.5)
 Total LOS, hours, mean (SD) 109.0 (95.9) 105.4 (69.3) 111.3 (108.5) 92.3 (53.7) 93.0 (54.2) 136.2 (95.5)
 Total inpatient cost, 2012 US$, mean (SD)a 10,508 (8109) 9604 (5691) 10,692 (9171) 8854 (4119) 8967 (4084) 11,308 (8345)

IRLOS infection-related length of stay, LOS length of stay, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible Staphylococcus aureus, SD standard deviation, WAC wholesale acquisition cost

aMultivariate analysis sample of 115 daptomycin and 106 vancomycin patients

bWAC cost estimates using “waste” algorithm

cThe P value was nonsignificant for all comparisons between daptomycin and vancomycin

dFour daptomycin and four vancomycin patients had other infection types

eIncludes known S. aureus infection for those patients with a culture; please note 5 daptomycin and 6 vancomycin patients were dropped from the MRSA/MSSA subgroup analyses mostly due to missing data